• References

    Bai YM, Yu SC, Lin CC.
    Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    J Clin Psychiatry. 2003;64:1342-1348.

    Damier P. Drug-induced dyskinesias.
    Curr Opin Neurol. 2009;22(4):394-399.

    Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H.
    Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.
    Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:985-996.

    McGrath JJ, Soares KV. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Database Syst Rev. 2006;CD000459.

    Meco G, Fabrizio E, Epifanio A, et al. Levetiracetam in tardive dyskinesia.
    Clin Neuropharmacol. 2006;29:265-268.

    Pham DQ, Plakogiannis R. Vitamin E supplementation in Alzheimer’s disease, Parkinson’s disease, tardive dyskinesia, and cataract: part 2.
    Ann Pharmacother. 2005;39(12):2065-72.

    Sachdev PS. The current status of tardive dyskinesia.
    Australian and New Zealand Journal of Psychiatry. 2000;34:355-369.

    Soares KV, McGrath JJ. The treatment of tardive dyskinesia: a systematic review and meta-analysis.
    Izophr Res.

    Tardive dyskinesia. EBSCO DynaMed website. Available at: Updated November 23, 2011. Accessed July 29, 2013.

    Tardive dyskinesia. National Alliance on Mental Illness website. Available at: Updated September 2003. Accessed July 29, 2013.

    Thema B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesias: passing the baton to pharmacogenetics.

  • Resources

    National Alliance on Mental Illness

    National Institute of Neurological Disorders and Stroke

  • Canadian Resources

    Canadian Mental Health Association